PITUITARY CORTICOTROPHIN (ACTH) PRODUCTION IN RHEUMATOID ARTHRITIS TESTED INDIRECTLY WITH METOPIRON (Su 4885)

BY

J. L. KALLIOMÄKI, N. T. KÄRKI, H. A. SAARIMAA, AND E. TALA

From the Departments of Medicine and Pharmacology, University of Turku, Finland

Metopiron [2-methyl-1,2-bis-3-pyridyl)-1-propylone; Su 4885] inhibits 11-β-hydroxylation in the adrenal cortex, and this inhibition is reflected as an increased production of ACTH in the anterior pituitary. It was found by Liddle, Estep, Kendall, Williams, and Townes (1959) that the pituitary production of ACTH in man can be measured with aid of Metopiron and numerous clinical studies have since been carried out which have shown that the Metopiron test can be employed as a reliable indirect method of evaluating the pituitary production of ACTH (e.g. Andersson, 1961; Faber, 1961; Gold, Kent, and Forsham, 1961).

In this paper we report results that obtained when the Metopiron test was applied to patients with rheumatoid arthritis.

Material and Methods

Our rheumatoid group comprised ten patients (3 male, 7 female; average age 53·7 yrs) who had not received steroid treatment for one year before the experiment.

The control group also comprised ten patients (3 male, 7 female; average age 46·0 yrs); the diagnoses of these patients are shown in Table II.

The patients in both groups were hospitalized during the whole experimental period of 6 days. The first, second, fifth, and sixth days were control days when Metopiron was not administered. On the third and fourth days the patients were all given 500 mg Metopiron orally every 6 hours.

The 24-hr urine was collected and analysed for total 17-hydroxy corticosteroids (17-OHCS) by a modification of the method of Jenkins, Forsham, Laidlaw, Reddy, and Thorn (1955).

Results

The results of the Metopiron tests for the rheumatoid and control groups are summarized in Tables I and II (opposite).

The differences between the mean values for the two groups are not statistically significant.

A tendency for a delayed reaction in the Metopiron test was evident in the rheumatoid group. The maximal average excretion of total 17-OHCS was recorded in the rheumatoid group on the fifth day (the day following the Metopiron administration), whereas it was recorded on the fourth day (the second day of Metopiron administration) in the control group.

Discussion

Our results seem to indicate that in rheumatoid patients the capacity of the pituitary to produce ACTH, as determined indirectly by the exogenous inhibition of 11-β-hydroxylation in the adrenal cortex, does not differ from the capacity in patients with various "non-collagenous" diseases. A tendency was noted in the rheumatoid patients for the response of the pituitary to be delayed, but it was not possible to determine on the basis of our results whether this finding was accidental or not. In an earlier study (Kalliomäki and Rauramo, 1960), it was found that urinary excretion of gonadotrophins is normal in female rheumatoid patients. Signs suggesting the thyrohypophyseal syndrome and an increased extracellular phase in rheumatoid arthritis (Kalliomäki and Holopainen, 1956; Kalliomäki, Kirpilä, Koskinen, and Laine, 1958) may reflect disturbances in the hypothalamo-pituitary system. It is possible that the delayed response of the anterior pituitary gland in the Metopiron test is also a manifestation of the same kind.

Metopiron has weak diuretic properties (it inhibits aldosterone production). Tables I and II show that the average total output of urine of the rheumatoid patients on the third, fourth, and fifth days was about half a litre larger than the average output in the control group. This may be taken as an indication of the above-mentioned predisposition to an increase in the extracellular fluid...
METOPIRON AND ACTH PRODUCTION

TABLE I
RESULTS OF METOPIRON TEST IN THE RHEUMATOID GROUP

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Age (yrs)</th>
<th>History of Rheumatoid Arthritis (yrs)</th>
<th>Stage of Rheumatoid Arthritis</th>
<th>Erythrocyte Sedimentation Rate (mm/hr)</th>
<th>Urinary Excretion of Total 17-OHCS (mg./24 hrs)</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Control</td>
<td>Metopiron</td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>44</td>
<td>III</td>
<td>100</td>
<td>19.2</td>
<td>12.6</td>
<td>12.8</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>33</td>
<td>III</td>
<td>100</td>
<td>1.8</td>
<td>3.4</td>
<td>9.1</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>52</td>
<td>III</td>
<td>84</td>
<td>2.0</td>
<td>3.8</td>
<td>9.5</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>38</td>
<td>III</td>
<td>117</td>
<td>3.9</td>
<td>2.5</td>
<td>8.4</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>63</td>
<td>III</td>
<td>74</td>
<td>8.4</td>
<td>5.6</td>
<td>9.5</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>69</td>
<td>II</td>
<td>43</td>
<td>2.5</td>
<td>2.9</td>
<td>9.2</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>35</td>
<td>IV</td>
<td>31</td>
<td>11.0</td>
<td>6.0</td>
<td>14.2</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>67</td>
<td>IV</td>
<td>50</td>
<td>4.8</td>
<td>1.3</td>
<td>8.8</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>19</td>
<td>IV</td>
<td>20</td>
<td>4.5</td>
<td>2.3</td>
<td>10.3</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>50</td>
<td>III</td>
<td>54</td>
<td>3.1</td>
<td>2.3</td>
<td>4.3</td>
</tr>
</tbody>
</table>

Mean Total 17-OHCS Excreted (mg./24 hrs) 6.3 4.3 8.9 8.9 9.4 4.9
Average Volume 24-hrs Urine (ml.) 1,080 990 1,415 1,105 1,210 925

TABLE II
RESULTS OF METOPIRON TEST IN THE CONTROL GROUP

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Age (yrs)</th>
<th>Diagnosis</th>
<th>Urinary Excretion of Total 17-OHCS (mg./24 hrs)</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Control</td>
<td>Metopiron</td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>64</td>
<td>Cardiac infarction</td>
<td>4.3</td>
<td>4.0</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>36</td>
<td>Cardiac infarction</td>
<td>3.2</td>
<td>1.8</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>43</td>
<td>Cardiac infarction</td>
<td>13.5</td>
<td>5.9</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>54</td>
<td>“Little stroke”</td>
<td>2.2</td>
<td>0.2</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>62</td>
<td>Pectic ulcer</td>
<td>8.2</td>
<td>5.8</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>52</td>
<td>Angina pectoris</td>
<td>12.0</td>
<td>13.9</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>47</td>
<td>Acute infection</td>
<td>4.1</td>
<td>5.0</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>54</td>
<td>Hypochromic anaemia</td>
<td>6.1</td>
<td>5.5</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>66</td>
<td>Pleural carcinoma</td>
<td>1,185</td>
<td>840</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>59</td>
<td>Hodgkin's disease</td>
<td>1,185</td>
<td>840</td>
</tr>
</tbody>
</table>

Mean Total 17-OHCS Excreted (mg./24 hrs) 6.6 5.5 8.5 9.9 8.1 5.5
Average Volume 24-hrs Urine (ml.) 1,185 840 1,238 1,095 1,000 920

Summary

The variation of the production of ACTH by the pituitary gland when 11-β-hydroxylation in the adrenal cortex is inhibited by Metopiron ("Su4885") has been followed by determining the mean daily excretion of total 17-hydroxycorticosteroids in ten patients with rheumatoid arthritis and in ten control patients with various internal diseases.

The response of the pituitary gland did not differ essentially in the rheumatoid and control groups, although a tendency for the response to be delayed was noted in the patients with rheumatoid arthritis.

REFERENCES

**ANNALS OF THE RHEUMATIC DISEASES**

**Production de corticotrophine (ACTH) dans l'arthrite rhumatismale sous l'influence indirecte de Metopiron (Su 4885)**

**RÉSUMÉ**

On étudia les variations dans la formation d'ACTH par l'hypophyse après l'inhibition de l'hydroxylation en position 11-B dans l'écorce surrenale par Metopiron (Su 4885), en déterminant l'élimination moyenne totale par jour des 17-hydroxycorticostéroides chez dix malades atteints d'arthrite rhumatismale et dix témoins souffrant de diverses autres maladies.

La réponse hypophysaire ne révéla pas de différence essentielle entre le groupe rhumatismal et le groupe témoin, mais chez les malades atteints d'arthrite rhumatismale on nota une tendance à répondre tardivement.

**Producción de corticotrofina hipofisaria (ACTH) suscitada indirectamente en artritis reumatoide con Metopiron (Su 4885)**

**SUMARIO**

Se estudiaron las variaciones en la producción de ACTH por la hipófisis, después de inhibir la 11-B-hidroxilación en la corteza suprarrenal con Metopiron (Su 4665), determinando la eliminación media diaria de 17-hidroxocorticosteroides en diez enfermos con artritis reumatoide y en diez testigos padeciendo de diversas otras enfermedades.

La respuesta hipofisaria no presentó ninguna diferencia esencial entre el grupo con artritis reumatoide y el de control, aunque en los enfermos con artritis reumatoide se notó tendencia a respuestas retardadas.
Pituitary Corticotrophin (ACTH) Production in Rheumatoid Arthritis tested indirectly with Metopiron (Su 4885)

J. L. Kalliomäki, N. T. Kärki, H. A. Saarimaa and E. Tala

*Ann Rheum Dis* 1961 20: 244-246
doi: 10.1136/ard.20.3.244

Updated information and services can be found at:

http://ard.bmj.com/content/20/3/244.citation

*These include:*

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/